Pfizer new developments......

Sweden has been hub for recombinant protein production and purification for more than decade, in places like Uppsala there are more than 50 big medium to small start-ups. Yesterday in some reports it was mentioned that Pfizer is said to invest $214.8 million (€150m) for its biotechnology facility in Strangnas (Sweden). The plant will be used to develop E.coli and yeast strains for recombinant protein production and the plant will also manufacture active pharmaceutical ingredients (API) for Pfizer’s human growth hormone (HGH) drugs Somavert (pegvisomant) and Genotropin (somatropin [rDNA origin]. The plant is expected to be fully operational in 2011.